ODI Pharma AB (publ) (NGM:ODI)
Sweden · Delayed Price · Currency is SEK 3.560
-0.320 (-8.25%)
At close: May 25, 2026
ODI Pharma AB Revenue
ODI Pharma AB had revenue of 10.93M SEK in the quarter ending December 31, 2025. This brings the company's revenue in the last twelve months to 20.04M, down -6.80% year-over-year. In the fiscal year ending June 30, 2025, ODI Pharma AB had annual revenue of 3.13M, down -85.94%.
Revenue (ttm)
20.04M
Revenue Growth
-6.80%
P/S Ratio
3.46
Revenue / Employee
20.04M
Employees
1
Market Cap
69.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 3.13M | -19.15M | -85.94% |
| Jun 30, 2024 | 22.29M | 22.15M | 15,880.34% |
| Jun 30, 2023 | 139.46K | -173.48K | -55.44% |
| Jun 30, 2022 | 312.94K | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NGS Group AB | 285.72M |
| Lohilo Foods AB | 198.07M |
| ABAS Protect AB | 87.41M |
| Obducat AB | 52.73M |
| Mediacle Group AB | 47.49M |
| Ramlösa shipping AB | 39.45M |
| GreenMerc AB | 23.79M |
| Katalysen Ventures AB | 1.65M |
ODI Pharma AB News
- 3 months ago - ODI Pharma AB Quarterly report: Q2 2026 - Filings
- 3 months ago - ODI Pharma AB Quarterly report: Q2 2026 - Filings
- 6 months ago - ODI Pharma AB Quarterly report: Q1 2026 - Filings
- 6 months ago - ODI Pharma AB Quarterly report: Q1 2026 - Filings
- 9 months ago - ODI Pharma AB Annual report: Q4 2025 - Filings
- 9 months ago - ODI Pharma AB Quarterly report: Q4 2025 - Filings
- 9 months ago - ODI Pharma AB Annual report: Q4 2025 - Filings
- 9 months ago - ODI Pharma AB Quarterly report: Q4 2025 - Filings